The effect of complimentary and alternative medicine products on laboratory testing

Seminars in Diagnostic Pathology

Volumn 26, Issue 1, 2009, Pages 38-48

  Rosecrans, Robert ^a   Dohnal, James C ^a  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

Author keywords

Black cohosh; Chan Su; Complimentary and alternative medicine; Cytochrome induction and inhibition; Glycyrrhiza; Hepatotoxicity; Kava kava; St. John's wort

Indexed keywords

AYURVEDIC DRUG; DIGOXIN; ECHINACEA EXTRACT; GARLIC EXTRACT; GINGER EXTRACT; GINKGO BILOBA EXTRACT; GINKGOLIDE; GINSENG EXTRACT; GINSENOSIDE; GLYCYRRHIZA EXTRACT; GLYCYRRHIZIC ACID; HEAVY METAL; HERBACEOUS AGENT; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; KAVA; PARTHENOLIDE; PESTICIDE; QUERCETIN; RUTOSIDE; TANACETUM PARTHENIUM EXTRACT; VALERIAN;

ALTERNATIVE MEDICINE; ARTICLE; BATCH PROCESS; BLEEDING; BLEEDING TIME; CLINICAL LABORATORY; COMA; DRUG CONTAMINATION; ECHINACEA; GARLIC; GINGER; GINKGO BILOBA; GINSENG; GLYCYRRHIZA; HEADACHE; HUMAN; HYPERICUM PERFORATUM; HYPERTENSION; KELP; LABORATORY TEST; LIVER TOXICITY; MANIA; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; TANACETUM PARTHENIUM;

CLINICAL LABORATORY TECHNIQUES; DIETARY SUPPLEMENTS; DRUG CONTAMINATION; HERB-DRUG INTERACTIONS; HUMANS; MEDICINE, TRADITIONAL; PLANT PREPARATIONS;

EID: 59249091663     PISSN: 07402570     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semdp.2008.12.002     Document Type: Article

References (76)

1. Miller L.G. Herbal medicines: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 158 (1998) 2200-2211
2. FDA/CFSAN Dietary Supplement Health and Education Act of 1994. http://www.cfsan.fda.gov/∼dms/dietsupp.html
3. Eisenberg D.M., Davis R.B., Ettner S., et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up survey. J Am Med Assoc 280 (1998) 1569-1575
4. National Center for Complementary and Alternative Medicine. National Institutes oh Health. The Use of Complimentary and Alternative Medicine in the United States. http://nccam.nih.gov./news/camsurvey_fs1.htm#spend
5. van der Sluijs C. Women's health during mid-life survey: the use of complementary and alternative medicine by symptomatic women transitioning through menopause in Sydney. Menopause 14 (2007) 397-403
6. Newton K.M., Buist D.S.M., Keenan N.L., et al. Use of alternative therapies for menopause symptoms: results of a population-based study. Obstet Gynecol 100 (2002) 18-25
7. Gollschewski S., Anderson D., Skerman H., et al. The use of complementary and alternative medications by menopausal women in South East Queensland. Womens Health Issues 14 (2004) 165-171
8. Norred C. Complementary and alternative medicine use by surgical patients. AORN J 76 (2002) 1013-1021
9. Goldman D., Rogovik A.L., Lai D., et al. Potential interactions of drug-natural health products and natural health products-natural health products among children. J Pediatr 152 (2008) 521-526
10. Wilson K., and Klein J. Adolescents' use of complementary and alternative medicine. Pediatr Res 47 (2000) 13a-13e
11. Goldman R.D., and Vohra S. Complementary and alternative medicine use by children visiting a pediatric emergency department. Can J Clin Pharmacol 11 (2004) e245-e256
12. Dunbabin D.W., Tallis G.A., Popplewell P.Y., et al. Lead poisoning from Indian herbal medicine (Ayurveda). Med J Aust 157 (1992) 835-836
13. Saper R.B., Kales K.N., Paquin J., et al. Heavy metal content of ayurvedic herbal medicine products. J Am Med Assoc 292 (2004) 2868-2873
14. Caldas E.D., and Machado L.L. Cadmium, mercury and lead in medical herbs in Brazil. Food Chem Toxicol 42 (2004) 599-603
15. Huang W.F., Wen K.C., Hsaio M.L., et al. Adulteration by synthetic therapeutic substances of traditional Chinese medicines in Taiwan. J Clin Pharmacol 37 (1997) 344-350
16. Lau G., Lo D.S., Yao Y.J., et al. A fatal case of hepatic failure possibly induced by nitrosofenfluramine: a case report. Med Sci Law 44 (2004) 252-263
17. Lau K.K., Lai C.K., Chan A.Y.W., et al. Phenytoin poisoning after using Chinese proprietary medicines. Hum Exp Toxicol 19 (2000) 385-386
18. Vander Stricht B.L., Parvais Q.E., Vanhaelen-Fastre R.J., et al. Safer use of traditional remedies. Remedies may contain cocktail of active drugs. Br Med J 308 (1994) 1162
19. Guengerich F. Cytochrome 450 enzymes. In: Ortiz de Montellano P. (Ed). Cytochrome P450. (ed 2) (1995), Plenum Press, New York, NY 473-575
20. Guengerich F. Cytochrome P450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39 (1999) 1-17
21. Sharpiro L., and Shear N. Drug interactions: proteins, pumps, and P450s. J Am Acad Dermatol 4 (2002) 467-484
22. Crespi C.L., Miller V.P., and Penman B.W. Microtiter plate assays for inhibition of human drug metabolizing cytochrome P450. Ann Biochem 48 (1997) 188-190
23. Meyer U.A., and Zanger U.M. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 37 (1997) 269-296
24. Deldoda R., and Westlake A. Herbal interactions involving cytochrome P450 enzymes. Toxicol Rev 23 (2004) 239-249
25. Sparreboom A., Cox M.C., Acharya M.R., et al. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 22 (2004) 2489-2503
26. Canigueral S., Tschopp R., Ambrosetti L., et al. The development of herbal medicinal products: quality, safety and efficacy as key factors. Pharmaceut Med 22 (2008) 107-118
27. Stedman C. Herbal heptotoxicity. Semin Liver Dis 22 (2002) 195-206
28. Seeff L.B. Herbal hepatotoxicity. Clin Liver Dis 11 (2007) 577-596
29. Estes J., Stolpman D., Olyaei A., et al. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminate hepatic failure. Arch Surg 138 (2003) 852-858
30. Krusekopf S., and Roots I. St. John's wort and its constituent hyperforin concordantly regulate expression of genes encoding enzymes involved in basic cellular pathways. Pharamacogenet Genomics 15 (2005) 817-829
31. Barone G.W., Gurely B.J., Ketel B.L., et al. Herbal supplements: a potential for drug interactions in transplant recipients. Transplantation 71 (2001) 330-340
32. Bauer S., Stromer E., Johne A., et al. Altercation of cyclosporine A pharmacokinetics and metabolism during treatment with St. John's wort in renal transplant patients. Br J Clin Pharmacol 55 (2003) 203-211
33. Mai I., Bauer S., Perloff E.S., et al. Hyperforin content determines the magnitude of the St. John's wort cyclosporine drug interaction. Clin Pharmocol 76 (2004) 330-340
34. Hebert M.F., Park J.M., Chen Y.L., et al. Effects of St. John's wort on tacrolimus pharmacokinetics in healthy volunteers. Clin Pharmacol 44 (2004) 89-94
35. Mai I., Stormer E., Bauer S., et al. Impact of St. John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant 18 (2003) 819-822
36. Milan F., Arnsten J., Klein R., et al. Use of complementary and alternative medicine in inner-city persons with or at risk of HIV infection. AIDS Patient Care STDS 22 (2008) 811-816
37. Ohno Y., and Hiska A. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. Clin Pharmacokinet 47 (2008) 669-680
38. Dasgupta A. Herbal supplements and therapeutic drug monitoring: focus on digoxin immunoassays and interactions with St. John's wort. Ther Drug Monit 30 (2008) 212-217
39. Draves D., Stieger B., Kullak-Ublick G.A., et al. Analysis of hypericin and psuedohypericin content in commercially available St. John's wort preparations. Can J Pharmacol 10 (2003) 114-118
40. Jamieson D.D., Duffield P.H., Cheng D., et al. Composition of the central nervous system activity of the aqueous and lipid extract of kava. Arch Int Pharmacodyn Ther 301 (1989) 66-80
41. Parkman C.A. Another FDA warning: kava supplements. Case Manager 13 (2002) 26-28
42. Rockwell S., Liu Y., and Higgins A. Alteration of the effects of cancer therapy agents on breast cancer cells by the herbal black cohosh. Breast Cancer Res Treat 90 (2005) 233-239
43. Dodin S., Akoum A., and Al-Akoum M. Synergistic cytotoxic effects of tamoxifen and black cohosh on MCF-7 and MDA-MB-231 human breast cancer cells: an in vitro study. Can J Physiol Pharmacol 85 (2007) 1153-1159
44. Teas J., Pino S., Critchley A., et al. Variability of iodine content in common commercially available edible seaweed. Thyroid 14 (2004) 836-841
45. Clark C.D., Bassett B., and Burge M.R. Effects of kelp supplementation on thyroid function in euthyroid subjects. Endro Pract 9 (2003) 363-369
46. Amster E., Tiwary A., and Schenker M.B. Case report: potential arsenic toxicosis secondary to herbal kelp supplement. Environ Health Perspect 115 (2007) 606-608
47. Elinav E., and Chajek-Shaul T. Licorice consumption causing severe hypokalemic paralysis. Mayo Clin Proc 78 (2003) 767-768
48. Cheng T. Herbal interactions with cardiac drugs. Arch Int Med 160 (2000) 870-871
49. Panesar N.S. Bufalin and unidentified substance(s) in traditional Chinese medicine cross-react in commercial digoxin assay. Clin Chem 38 (1992) 2155-2256
50. Dasgupta A., Actor J., Olsen M., et al. Effect of Asian and Siberian ginseng on serum digoxin measurement by five digoxin immunoassyas: significant variation in digoxin-like immunoreactivity among commercial ginsengs. Am J Clin Pathol 119 (2003) 298-303
51. Le Bars P.L., Kieser M., and Itil K.Z. A 26-week analysis of a double-blind, placebo-controlled trail of Ginkgo biloba extract EGb761 in dementia. Demet Geriatr Cogn Disord 11 (2000) 230-237
52. VanDongen M., van Rossum E., Kessels A., et al. Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. J Clin Epidemiol 56 (2003) 367-376
53. Vellas B., and Grandjean H. Association of Alzheimer's disease onset with ginko biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study. J Gerontol A Biol Sci Med Sci 58 (2003) 372-377
54. Esrnst E., and Pittler M.H. Ginkgo biloba for dementia: a systemic review of double-blind, placebo-controlled trials. Clin Drug Invest 17 (1999) 301-308
55. Bridi R., Crossetti F.P., Steffen V.M., et al. The antioxidant activity of standardized extract of Ginkgo biloba (EGb761) in rats. Phytother Res 15 (2001) 449-451
56. Ernst E., and Stevinson C. Ginkgo biloba for tinnitus: a review. Clin Otolaryngol Allied Sci 24 (1999) 164-167
57. Peters H., Kieser M., and Holscher U. Demonstration of the efficacy of Ginkgo biloba special extract Rgb761 on intermittent claudification, a placebo-controlled, double blinded trial. Vasa 27 (1998) 105-110
58. Manocha A., Pillai K.K., and Husain S.Z. Influence of Ginkgo biloba on the effect of anticonvulsants. Indian J Pharmacol 28 (1966) 84-87
59. Izzo A.A., and Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 61 (2001) 2163-2175
60. Mauro V.F., Mauro L.S., Kleshinski J.F., et al. Impact of Ginkgo biloba on the pharmacokinetics of digoxin. Am J Ther 10 (2003) 247-251
61. Kaufman D.W., Kelly J.P., Rosenburg L., et al. Recent patterns of medication use in the ambulant adult population in the United States. J Am Med Assoc 287 (2002) 337-344
62. Volger B.K., Pitller M.H., and Ernst E. The efficacy of ginseng: a systematic review of randomised controlled clinical trials. Eur J Clin Pharmacol 55 (1999) 567-575
63. Wesnes K.A., Ward T., McGinty A., et al. The memory enhancing effects of Ginko biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology 152 (2000) 353-361
64. Ernst E., and Pittler M.H. Ginko biloba for dementia: a systematic review of double-blinded placebo-controlled trials. Clin Drug Invest 17 (1999) 301-308
65. Izzo A.A., and Ernst E. Interactions between herbal medicines and prescribed drugs: a sysmtematic review. Drugs 61 (2001) 2163-2175
66. Coon J.T., and Ernst E. Panax ginseng: a systematic review of adverse effects and drug interactions. Drug Saf 25 (2002) 323-344
67. Johnson E.S., Kadam N.O., Hylands D.M., et al. Efficacy of feverfew as prophylactic treatment of migraine. Br Med J 291 (1985) 569-573
68. De Weerdt C.J., Bootsma H.P.R., and Hendricks H. Herbal medicines in migraine prevention: randomized double-blinded placebo controlled crossover trial of a feverfew preparation. Phytomedicine 3 (1996) 252-230
69. Pattrick M., Heptinsall S., and Doherty M. Feverfew in rheumatoid arthritis: a double-blinded, placebo controlled study. Ann Rheum Dis 48 (1989) 547-549
70. Sumner H., Salan U., Knight D.W., et al. Inhibition of 5-lipoxygease and cyclo-oxygenase in leukocytes by Feverfew: involvement of sesquiterpene lactonew and other components. Biochem Pharmacol 43 (1992) 704-708
71. Melchart D., Linde K., Worku F., et al. Results of five randomized studies on the immunomodulatory activity of preparations of Echinacea. J Alt Comp Med 1 (1995) 145-160
72. Turner R.B., Riker D.K., and Gangemi J.D. Ineffectiveness of Echiinacea for prevention of experimental rhinovirus colds. Antimicrob Agents Chemother 44 (2000) 1708-1709
73. Ernst E. The risk-benefit profile of commonly used herbal therapies: Ginkgo, St John's Wort, Ginseng, Echinacea, Saw Palmetto and Kava Ann. Intern Med 136 (2002) 42-53
74. Panesar N.S. Bufalin and inidentified substances(s) in traditional Chinese medicine cross-react in commercial digoxin assay. Clin Chem 38 (1992) 2155-2156
75. Chow L., Johnson M., Wells A., et al. Effect of traditional Chinese medicines Chan-Su, Lu-Shen-Wan, Dan Shen and Asian giseng on serum digoxin measurement by Tina-quant (Roche) and Synchron LX system (Beckman) digoxin immunoassays. J Clin Lab Anal 17 (2003) 22-27
76. Dasgupta A., Biddle D., Wells A., et al. Positive and negative interference of Chinese medicine Chan Su in serum digoxin measurement: elimination of interference by using monoclonal chemilumiescent digoxin assay or monitoring free digoxin concentration. Am J Clin Pathol 114 (2000) 174-179